Business Context and Reporting Period
Company: Prana Biotechnology Limited (Note: Request metadata listed "Alterity Therapeutics Ltd," but the filing text identifies the registrant as Prana Biotechnology Limited).
Filing Type: Form 6-K (Report of Foreign Private Issuer).
Reporting Period: June 2009 (Filing date: June 17, 2009).
Business Overview: Prana is a development-stage enterprise focused on research and development into therapies for neurodegenerative diseases (e.g., Alzheimer's, Parkinson's) based on metal-mediated oxidative stress. The filing discloses a Consultancy Services Agreement with Dr. Ashley Bush and a subsequent amendment regarding termination terms.
Key Financial Metrics and Contractual Obligations
The filing does not contain audited financial statements, revenue, profit, or cash flow data for the period. It details specific contractual financial obligations:
- Annual Consultancy Fee: USD $100,000 per annum, payable in monthly installments.
- Fee Adjustment: Subject to annual increases based on the U.S. Consumer Price Index.
- Equity Compensation (Bonus Package):
- 1,650,000 shares vesting over 2 years (25% every 6 months).
- 825,000 options to acquire shares vesting over 2 years.
- Exercise price for options: AU$0.50 per share.
- Share Acquisition Package: Right to purchase up to 5,000,000 additional shares upon achieving specific clinical or licensing milestones.
- Royalties: 5% of income derived from exploitation of new intellectual property contributed by the Consultant for 20 years.
Material Changes and Amendments
Termination Notice Period Amendment: A Letter Agreement dated November 14, 2007, amended the original Consultancy Services Agreement (dated January 8, 2004).
- Previous Term: 90 days written notice required for termination by either party.
- New Term: Reduced to 30 days written notice.
- Rationale: The Company's auditors required a reduction in potential termination liabilities to avoid a "going concern" qualification in financial reports and to free up cash for operational use.
Outlook, Risks, and Management Commentary
Liquidity and Going Concern: Management explicitly stated that the amendment to the termination notice period was driven by the need to manage cash reserves to satisfy auditor requirements regarding the company's ability to continue as a going concern. This indicates potential liquidity constraints.
Intellectual Property Risks: The agreement includes complex provisions regarding the ownership of inventions. Prana owns inventions developed during the term, except those supported by MGH (Massachusetts General Hospital) resources or funding. Disputes regarding conflict of interest or MGH policy compliance are subject to mediation.
Operational Risks: The company relies heavily on the Consultant's availability (40 days per year) and the achievement of clinical milestones (e.g., Phase II trial results for Clioquinol) to unlock significant equity incentives.
Investor Verification Checklist
- Verify the company's current cash position and whether the "going concern" risk mentioned in the 2007 amendment has been resolved.
- Confirm the status of the Phase II clinical trials for Clioquinol, as this is a key milestone for the Share Acquisition Package.
- Review the total number of shares outstanding to assess the dilution impact of the 1,650,000 bonus shares and potential 5,000,000 acquisition shares.
- Check for any subsequent filings regarding the Consultant's status or any disputes arising from the MGH conflict of interest clauses.
- Clarify the discrepancy between the request metadata ("Alterity Therapeutics") and the filing text ("Prana Biotechnology").